# Gyala Therapeutics

Source: https://onco.cc/companies/gyala-therapeutics/  
OnCo record `gyala-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gyala Therapeutics develops CAR-T cell therapy, in which a patient's own immune cells are modified to attack leukaemia. Its first product targets a protein called CD84 and is in an early trial in acute myeloid leukaemia and T-cell acute lymphoblastic leukaemia that has come back or not responded.

## Summary

Gyala Therapeutics was founded in 2020 as a spin-off of Hospital Clinic Barcelona and the IDIBAPS research institute, according to the company. GYA01 is a CAR-T cell therapy targeting CD84. Spain's AEMPS authorised a phase 1/2a, open-label, single-arm trial (NCT07471789) in relapsed or refractory acute myeloid leukaemia and T-cell acute lymphoblastic leukaemia, with recruitment announced in February 2026 at Hospital La Fe in Valencia and Hospital Clinic Barcelona. In October 2024 the company announced 3 million euros from CDTI Innovation (Innvierte programme), Nara Capital and Invivo Partners, following a 1.5 million euro seed round in 2020. Its first registered cancer trial, NCT07471789, was posted on ClinicalTrials.gov in March 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Barcelona
- Type: cell-therapy
- Website: https://gyalatx.com/

## Notes

- The website does not state a headquarters address; Barcelona is inferred from the spin-off from Hospital Clinic Barcelona and IDIBAPS.
- The company's own URLs use GYA001 and its text GYA01 for the same product.
- CD84 has no OnCo target record and is named in text only.
- Company website and releases read on 29 October 2026.

## Sources

- Official website: https://gyalatx.com/
- Gyala: phase 1/2a trial of GYA01 begins (February 2026): https://gyalatx.com/gyala-therapeutics-initiates-phase-i-iia-clinical-trial-of-a-car-t-cell-therapy-for-acute-leukemias-with-limited-treatment-options/

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- trials: [Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).](https://onco.cc/trials/nct07471789/)

---
JSON: https://onco.cc/api/v1/entities/gyala-therapeutics.json